Literature DB >> 7687061

Mechanism of resistance of human immunodeficiency virus type 1 to 2',3'-dideoxyinosine.

J L Martin1, J E Wilson, R L Haynes, P A Furman.   

Abstract

A molecular clone containing the wild-type reverse transcriptase (RT) coding region of human immunodeficiency virus type 1 (HIV-1) was constructed, and site-directed mutagenesis was used to introduce mutations--Leu74-->Val (L74V), T215Y, and the combination L74V/T215Y--into the RT coding region. The proteins were purified by immunoaffinity chromatography. Assays were performed with mutant and wild-type RT to determine substrate and inhibitor specificity. All three mutant enzymes catalyzed the incorporation of substrate 2'-deoxynucleoside 5'-triphosphates (dNTPs) as efficiently as wild-type HIV-1 RT. Small changes were observed in the Km values for dNTPs with all three mutant enzymes, while more significant changes were noted in sensitivity to nucleoside 5'-triphosphate analogues that inhibit the enzyme activity. Results suggest that altered substrate recognition by the HIV-1 RT is involved in the mechanism of resistance.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687061      PMCID: PMC46882          DOI: 10.1073/pnas.90.13.6135

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

2.  3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.

Authors:  M H St Clair; C A Richards; T Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  Elementary steps in the DNA polymerase I reaction pathway.

Authors:  F R Bryant; K A Johnson; S J Benkovic
Journal:  Biochemistry       Date:  1983-07-19       Impact factor: 3.162

4.  A molecular clone of HTLV-III with biological activity.

Authors:  A G Fisher; E Collalti; L Ratner; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

5.  Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions.

Authors:  A D Hoffman; B Banapour; J A Levy
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

6.  Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities.

Authors:  P A Furman; D M Coen; M H St Clair; P A Schaffer
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103

7.  Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

Authors:  Y K Chow; M S Hirsch; D P Merrill; L J Bechtel; J J Eron; J C Kaplan; R T D'Aquila
Journal:  Nature       Date:  1993-02-18       Impact factor: 49.962

8.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

9.  Structural characterization of reverse transcriptase and endonuclease polypeptides of the acquired immunodeficiency syndrome retrovirus.

Authors:  M M Lightfoote; J E Coligan; T M Folks; A S Fauci; M A Martin; S Venkatesan
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

10.  Characterization of the RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus).

Authors:  M A Rey; B Spire; D Dormont; F Barre-Sinoussi; L Montagnier; J C Chermann
Journal:  Biochem Biophys Res Commun       Date:  1984-05-31       Impact factor: 3.575

View more
  33 in total

1.  Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.

Authors:  Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stephanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.

Authors:  Y Kew; H Salomon; L R Olsen; M A Wainberg; V R Prasad
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

5.  Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.

Authors:  Hua-Poo Su; Youwei Yan; G Sridhar Prasad; Robert F Smith; Christopher L Daniels; Pravien D Abeywickrema; John C Reid; H Marie Loughran; Maria Kornienko; Sujata Sharma; Jay A Grobler; Bei Xu; Vinod Sardana; Timothy J Allison; Peter D Williams; Paul L Darke; Daria J Hazuda; Sanjeev Munshi
Journal:  J Virol       Date:  2010-05-19       Impact factor: 5.103

6.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

7.  Studies of neutralizing monoclonal antibody to human immunodeficiency virus type 1 reverse transcriptase: antagonistic and synergistic effects in reactions performed in the presence of nucleoside and nonnucleoside inhibitors, respectively.

Authors:  Z Gu; X Li; Y Quan; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

9.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

10.  Biophysical and enzymatic properties of the simian and prototype foamy virus reverse transcriptases.

Authors:  Maximilian J Hartl; Florian Mayr; Axel Rethwilm; Birgitta M Wöhrl
Journal:  Retrovirology       Date:  2010-01-29       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.